SAN DIEGO, Sept. 19, 2017 /PRNewswire/ -- MEI Pharma,
Inc. (Nasdaq: MEIP), an oncology company focused on the clinical
development of novel therapies for cancer, announced today that
Daniel P. Gold, Ph.D., President and
Chief Executive Officer, will present at the Cantor Fitzgerald
Global Healthcare Conference on Tuesday,
September 26, 2017 at 3:25 p.m.
Eastern time from the InterContinental New York Barclay
Hotel. A live webcast of the presentation can be accessed at
www.meipharma.com. A replay will be available approximately one
hour after the presentation.
About MEI Pharma
MEI Pharma, Inc. (Nasdaq: MEIP) is a San Diego-based oncology company focused on
the clinical development of novel therapies for cancer. The
Company's portfolio of drug candidates includes Pracinostat, an
oral HDAC inhibitor that is partnered with Helsinn Healthcare, SA.
Pracinostat has been granted Breakthrough Therapy Designation from
the FDA for use in combination with azacitidine for the treatment
of patients with newly diagnosed AML who are unfit for intensive
chemotherapy. Pracinostat is also being developed in combination
with azacitidine in patients with high and very high-risk MDS. MEI
Pharma's clinical development pipeline also includes ME-401, a
highly differentiated oral PI3K delta inhibitor currently in a
Phase Ib study in patients with relapsed/refractory CLL or
follicular lymphoma, and voruciclib, an oral, selective CDK
inhibitor shown to suppress MCL1, a known mechanism of resistance
to BCL2 inhibitors. The Company is also developing ME-344, a novel
mitochondrial inhibitor currently in an investigator-sponsored
study in combination with bevacizumab for the treatment of
HER2-negative breast cancer. Pracinostat, ME-401, voruciclib and
ME-344 are investigational agents and are not approved for use in
the U.S. For more information, please visit www.meipharma.com.
Under U.S. law, a new drug cannot be marketed until it has
been investigated in clinical studies and approved by the FDA as
being safe and effective for the intended use. Statements included
in this press release that are not historical in nature are
"forward-looking statements" within the meaning of the "safe
harbor" provisions of the Private Securities Litigation Reform Act
of 1995. You should be aware that our actual results could differ
materially from those contained in the forward-looking statements,
which are based on management's current expectations and are
subject to a number of risks and uncertainties, including, but not
limited to, our failure to successfully commercialize our product
candidates; costs and delays in the development and/or FDA
approval, or the failure to obtain such approval, of our product
candidates; uncertainties or differences in interpretation in
clinical trial results; our inability to maintain or enter into,
and the risks resulting from our dependence upon, collaboration or
contractual arrangements necessary for the development,
manufacture, commercialization, marketing, sales and distribution
of any products; competitive factors; our inability to protect our
patents or proprietary rights and obtain necessary rights to third
party patents and intellectual property to operate our business;
our inability to operate our business without infringing the
patents and proprietary rights of others; general economic
conditions; the failure of any products to gain market acceptance;
our inability to obtain any additional required financing;
technological changes; government regulation; changes in industry
practice; and one-time events. We do not intend to update any of
these factors or to publicly announce the results of any revisions
to these forward-looking statements.
View original
content:http://www.prnewswire.com/news-releases/mei-pharma-to-present-at-cantor-fitzgerald-global-healthcare-conference-300521737.html
SOURCE MEI Pharma, Inc.